Protocol Ledger

NCT03597503 · Phase III · TERMINATED

Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

Interventional Phase III clinical trial protocol NCT03597503 sponsored by Supernus Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-31 Enrollment: 41 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03597503
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)41 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03597503
Protocol FieldVerified Registry Value
NCT IdentifierNCT03597503
Consolidated Lead SponsorSupernus Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment41 participants (ACTUAL)
Registered Start Date2018-07-31
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03597503
Hospital Research SiteLocationSite Profile
Clinical Neuroscience Solutions, Inc.Jacksonville, FLOpen Hospital Dossier ->
Atlanta Center for Medical ResearchAtlanta, GAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI